Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis was first described in 1882 by Friedrich Daniel von Reckling hausen, a German pathologist. Neurofibroma is a benign peripheral nerve sheath tumor that consists of Schwann cells, associated or unassociated with axons, perineural cells, and fibroblasts. Whenever possible, the treatment of choice should be surgical, but the management depends on the location and growth pattern. We present the case of a patient with left axillary neurofibroma without neurofibromatosis (NF) in whom surgery was delayed due to involvement of the brachial plexus, so was sent to radiotherapy, planned and treated with volumetrically modulated arc therapy (VMAT). Keywords: Neurofibroma; VMAT; Radiotherapy; Axillary Tumor; INCART Abbreviations: NF: Neurofibromatosis; VMAT: Volumetrically Modulated Arc Therapy; CRO: Radiation Oncology Center; INCART: Institute Rosa Emilia Sánchez Pérez de Tavares; ...

  Cancer Therapy & Oncology International Journal Abstract Multiple myeloma (MM) is a malignant disorder of antibody-producing clonal plasma cells. It is the second most common hematologic neoplasia worldwide [1]. Despite recent advances in myeloma treatment (high-dose chemotherapy followed by autologous stem cell transplantation, novel immunomodulatory drugs, and proteasome inhibitors); MM remains largely incurable with chemotherapy [2]. This is mostly due to the persistence of minimal residual disease (MRD), which leads to high relapse rates [2]. Furthermore, the prognosis of MM patients who become refractory to recently developed novel agents is very poor [1]. Abbreviations: MM: Multiple Myeloma; MRD: Minimal Residual Disease; PD-L1: Programmed Cell Death Ligand; MDSCs: Myeloid-Derived Suppressor Cells; ACT: Adoptive Cellular Therapy; SLAMF7: Signaling Lymphocyte Activating-Molecule Family Member 7; ADCC: Antibody-Dependent Cellular Cytotoxicity;...

  Cancer Therapy & Oncology International Journal Abstract Management of patients with glioblastoma multiform requires the concerted efforts of multiple healthcare professionals, including pharmacists. Pharmacists across different practice settings may encounter patients being treated for glioblastoma multiforme. The oral chemotherapy temozolomide is a standard of care forglioblastoma multiforme, with dosing regimens and cycles that require dispensing considerations by the pharmacist as well as careful patient monitoring. Pharmacists should be able to direct the patient with glioblastoma multiforme to payment assistance for this drug as well. Bevacizumab is used to increase progression-free survival in recurrent glioblastoma multiforme, and pharmacists can also aid in the dosing and monitoring of this agent. Sequelae of glioblastoma multiforme include brain edema, seizures, venous thromboembolism, depression, and fatigue. Management of sequelae may includ...

  Cancer Therapy & Oncology International Journal    Abstract Prostate cancer within a younger cohort of men continues to be an increasing problem. With a younger population, greater expectations are present, from erectile function, to continence to oncological outcomes. Significant prostate cancer is increasingly diagnosed in younger men, less than 55 years [1]. In a non-screened population young patients are choosing radical surgery for intermediate and high risk disease [1]. This patient group have high expectations with regards to oncological and functional outcomes. The next question arises, what can we do to improve outcomes? Keywords: robotic radical prostatectomy, outcomes Abbreviations: ERSPC: European Randomized Study of Screening for Prostate Cancer; AUA: American Urological Association Mini Review Early-onset prostate cancer (<55 years), dif...

  Cancer Therapy & Oncology International Journal Mini Review Robotic Radical Partial Nephrectomy: Keep Pushing the Boundaries *Sanchia Goonewardene The Royal Free and UCL, UK Submission: October 26, 2016; Published: October 18, 2016 *Corresponding author: Sanchia Goonewardene, The Royal Free and UCL, NW3 2NG London, UK How to cite this article: Sanchia G. Robotic Radical Partial Nephrectomy: Keep Pushing the Boundaries. Canc Therapy & Oncol Int J. 2016; 2(1):555580. DOI: 10.19080/CTOIJ.2016.02.555580 Abstract The purpose of robotic radical partial nephrectomy is to ensure oncological clearance, whilst maintaining renal function. Main renal artery clamping during robotic partial nephrectomy (RPN) may compromise post-operative renal function [1]. Recent technologic advances mean resectional technique and outcomes can be improved. Specifically, robotic platforms, with robotic-assisted instrumentation, have ...